Fda'S Fast Track Designation For Oral Orismilast Underscores The Urgent Need For New Treatment Option With Potential To Fulfil The Unmet Medical Needs For People Affected By Atopic Dermatitis (Ad)Ad Is The Most Common Chronic Inflammatory Skin Disease In The Developed WorldOrismilast Is A Next Generation Pde4 Inhibitor With Broad Anti-Inflammatory Properties Also In Development For The Treatment Of Psoriasis And Hidradenitis Suppurativa (Hs)Union Therapeutics A/S, A Privately-Held, Multi-Asset, Clinical Stage, Pharmaceutical Company Focused On Immunology And Infectious Diseases, Today Announced That The Us Food And Drug Administration (Fda) Has Granted Fast Track Designation To Oral Orismilast For The Treatment Of Moderate To Severe Ad. The Fda'S Fast Track Designation Is Intended To Facilitate The Development And Review Of Drug Candidates That Treat Serious Conditions And Address An Unmet Medical Need. A Drug Candidate That Receives Fast Track Designation Is Eligible For More Frequent Interaction With The Fda To Discuss The Drug Candidate'S Development Plan As Well As Eligibility For Rolling Review And Priority Review.Kim Kj
